Suppressor Role of Activating Transcription Factor 2 (ATF2) in Skin Cancer

Overview

Journal Proc Natl Acad Sci U S A

Specialty Science

Date 2008 Jan 30

PMID 18227516

Citations 48

Authors

Anindita Bhoumik

Boris Fichtman

Charles DeRossi

Wolfgang Breitwieser

Harriet M Kluger

Sean Davis

Antonio Subtil

Paul Meltzer

Stan Krajewski

Nic Jones

Zeev Ronai

Affiliations

Soon will be listed here.

Abstract

Activating transcription factor 2 (ATF2) regulates transcription in response to stress and growth factor stimuli. Here, we use a mouse model in which ATF2 was selectively deleted in keratinocytes. Crossing the conditionally expressed ATF2 mutant with K14-Cre mice (K14.ATF2(f/f)) resulted in selective expression of mutant ATF2 within the basal layer of the epidermis. When subjected to a two-stage skin carcinogenesis protocol [7,12-dimethylbenz[a]anthracene/phorbol 12-tetradecanoate 13-acetate (DMBA/TPA)], K14.ATF2(f/f) mice showed significant increases in both the incidence and prevalence of papilloma development compared with the WT ATF2 mice. Consistent with these findings, keratinocytes of K14.ATF2(f/f) mice exhibit greater anchorage-independent growth compared with ATF2 WT keratinocytes. Papillomas of K14.ATF2(f/f) mice exhibit reduced expression of presenilin1, which is associated with enhanced beta-catenin and cyclin D1, and reduced Notch1 expression. Significantly, a reduction of nuclear ATF2 and increased beta-catenin expression were seen in samples of squamous and basal cell carcinoma, as opposed to normal skin. Our data reveal that loss of ATF2 transcriptional activity serves to promote skin tumor formation, thereby indicating a suppressor activity of ATF2 in skin tumor formation.

Citing Articles

Survival expectations in melanoma patients: a molecular prognostic model associated with aging.

Zhang N, Qiu X, Chen X, Du C, Dong J, Li X Discov Oncol. 2025; 16(1):253.

PMID: 40019657 PMC: 11874052. DOI: 10.1007/s12672-025-01971-z.

Emerging roles of activating transcription factor 2 in the development of breast cancer: a comprehensive review.

Amarah A, Elsabagh A, Ouda A, Karen O, Ferih K, Elmakaty I Precis Clin Med. 2023; 6(4):pbad028.

PMID: 37955015 PMC: 10639104. DOI: 10.1093/pcmedi/pbad028.

FIBP is a prognostic biomarker and correlated with clinicalpathological characteristics and immune infiltrates in acute myeloid leukemia.

Ma M, Xu L, Cui W, Huang Y, Chi G Discov Oncol. 2023; 14(1):97.

PMID: 37310595 PMC: 10264308. DOI: 10.1007/s12672-023-00723-1.

Emerging roles of activating transcription factor (ATF) family members in tumourigenesis and immunity: Implications in cancer immunotherapy.

Chen M, Liu Y, Yang Y, Qiu Y, Wang Z, Li X Genes Dis. 2022; 9(4):981-999.

PMID: 35685455 PMC: 9170601. DOI: 10.1016/j.gendis.2021.04.008.

The two-faced role of ATF2 on cisplatin response in gastric cancer depends on p53 context.

Xu L, Wang J, Zhang D, Song L, Wu H, Wang J Cell Biosci. 2022; 12(1):77.

PMID: 35641966 PMC: 9153165. DOI: 10.1186/s13578-022-00802-w.

References

Kang D, Soriano S, Xia X, Eberhart C, De Strooper B, Zheng H . Presenilin couples the paired phosphorylation of beta-catenin independent of axin: implications for beta-catenin activation in tumorigenesis. Cell. 2002; 110(6):751-62. DOI: 10.1016/s0092-8674(02)00970-4. View

Berger A, Kluger H, Li N, Kielhorn E, Halaban R, Ronai Z . Subcellular localization of activating transcription factor 2 in melanoma specimens predicts patient survival. Cancer Res. 2003; 63(23):8103-7. View

Xia X, Qian S, Soriano S, Wu Y, Fletcher A, Wang X . Loss of presenilin 1 is associated with enhanced beta-catenin signaling and skin tumorigenesis. Proc Natl Acad Sci U S A. 2001; 98(19):10863-8. PMC: 58565. DOI: 10.1073/pnas.191284198. View

Van Dam H, Wilhelm D, Herr I, Steffen A, Herrlich P, Angel P . ATF-2 is preferentially activated by stress-activated protein kinases to mediate c-jun induction in response to genotoxic agents. EMBO J. 1995; 14(8):1798-811. PMC: 398273. DOI: 10.1002/j.1460-2075.1995.tb07168.x. View

Gupta S, Campbell D, Derijard B, Davis R . Transcription factor ATF2 regulation by the JNK signal transduction pathway. Science. 1995; 267(5196):389-93. DOI: 10.1126/science.7824938. View

Yuspa S . The pathogenesis of squamous cell cancer: lessons learned from studies of skin carcinogenesis--thirty-third G. H. A. Clowes Memorial Award Lecture. Cancer Res. 1994; 54(5):1178-89. View

Bhoumik A, Gangi L, Ronai Z . Inhibition of melanoma growth and metastasis by ATF2-derived peptides. Cancer Res. 2004; 64(22):8222-30. DOI: 10.1158/0008-5472.CAN-04-0714. View

Li J, Dong Z, Dawson M, Colburn N . Inhibition of tumor promoter-induced transformation by retinoids that transrepress AP-1 without transactivating retinoic acid response element. Cancer Res. 1996; 56(3):483-9. View

He T, Sparks A, Rago C, Hermeking H, Zawel L, DA COSTA L . Identification of c-MYC as a target of the APC pathway. Science. 1998; 281(5382):1509-12. DOI: 10.1126/science.281.5382.1509. View

10.

Lefort K, Mandinova A, Ostano P, Kolev V, Calpini V, Kolfschoten I . Notch1 is a p53 target gene involved in human keratinocyte tumor suppression through negative regulation of ROCK1/2 and MRCKalpha kinases. Genes Dev. 2007; 21(5):562-77. PMC: 1820898. DOI: 10.1101/gad.1484707. View

11.

Huguier S, Baguet J, Perez S, Van Dam H, Castellazzi M . Transcription factor ATF2 cooperates with v-Jun to promote growth factor-independent proliferation in vitro and tumor formation in vivo. Mol Cell Biol. 1998; 18(12):7020-9. PMC: 109284. DOI: 10.1128/MCB.18.12.7020. View

12.

Bowden G, Schneider B, Domann R, Kulesz-Martin M . Oncogene activation and tumor suppressor gene inactivation during multistage mouse skin carcinogenesis. Cancer Res. 1994; 54(7 Suppl):1882s-1885s. View

13.

Bianchi A, Fischer S, Robles A, Rinchik E, Conti C . Overexpression of cyclin D1 in mouse skin carcinogenesis. Oncogene. 1993; 8(5):1127-33. View

14.

Roop D, Lowy D, Tambourin P, Strickland J, Harper J, Balaschak M . An activated Harvey ras oncogene produces benign tumours on mouse epidermal tissue. Nature. 1986; 323(6091):822-4. DOI: 10.1038/323822a0. View

15.

Kerppola T, Curran T . Selective DNA bending by a variety of bZIP proteins. Mol Cell Biol. 1993; 13(9):5479-89. PMC: 360261. DOI: 10.1128/mcb.13.9.5479-5489.1993. View

16.

FINCH J, Albino H, Bowden G . Quantitation of early clonal expansion of two mutant 61st codon c-Ha-ras alleles in DMBA/TPA treated mouse skin by nested PCR/RFLP. Carcinogenesis. 1996; 17(12):2551-7. DOI: 10.1093/carcin/17.12.2551. View

17.

Bhoumik A, Huang T, Ivanov V, Gangi L, Qiao R, Woo S . An ATF2-derived peptide sensitizes melanomas to apoptosis and inhibits their growth and metastasis. J Clin Invest. 2002; 110(5):643-50. PMC: 151112. DOI: 10.1172/JCI16081. View

18.

Song W, Nadeau P, Yuan M, Yang X, Shen J, Yankner B . Proteolytic release and nuclear translocation of Notch-1 are induced by presenilin-1 and impaired by pathogenic presenilin-1 mutations. Proc Natl Acad Sci U S A. 1999; 96(12):6959-63. PMC: 22024. DOI: 10.1073/pnas.96.12.6959. View

19.

Shtutman M, Zhurinsky J, Simcha I, Albanese C, DAmico M, Pestell R . The cyclin D1 gene is a target of the beta-catenin/LEF-1 pathway. Proc Natl Acad Sci U S A. 1999; 96(10):5522-7. PMC: 21892. DOI: 10.1073/pnas.96.10.5522. View

20.

Robles A, Rodriguez-Puebla M, Glick A, Trempus C, Hansen L, Sicinski P . Reduced skin tumor development in cyclin D1-deficient mice highlights the oncogenic ras pathway in vivo. Genes Dev. 1998; 12(16):2469-74. PMC: 317082. DOI: 10.1101/gad.12.16.2469. View